Renaissance Capital logo

MiNK Therapeutics Priced, Nasdaq: INKT

Phase 1 biotech developing allogeneic NK T cells for cancer and other diseases.

Industry: Health Care

Latest Trade: $12.13 +0.03 (+0.2%)

First Day Return: 0.0%

Return from IPO: +0.8%

Industry: Health Care

We are a clinical stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly versatile application for therapeutic development in cancer and immune diseases. We are leveraging our platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells, and anticipate having multiple clinical and preclinical readouts in 2021 and 2022. Our most advanced product candidate, AGENT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy that is currently in multiple Phase 1 clinical trials. We have commenced a Phase 1 clinical trial of AGENT-797 for the treatment of multiple myeloma and expect to report top-line data from this trial in the fourth quarter of 2021. In addition, in August 2021, we received FDA clearance to initiate a clinical study for the treatment of solid tumors, which we intend to advance as our lead indication for AGENT-797 as a monotherapy and in combination with checkpoint inhibitors.
more less
IPO News for MiNK Therapeutics
more
IPO Data
IPO File Date 09/14/2021
Offer Price $12.00
Price Range $12.00 - $14.00
Offer Shares (mm) 3.3
Deal Size ($mm) $40
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/14/2021
Offer Price $12.00
Price Range $12.00 - $14.00
Offer Shares (mm) 3.3
Deal Size ($mm) $40
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters New York, NY
Founded 2017
Employees 34
Website www.minktherapeutics.com